EVFM Evofem Biosciences, Inc.
Financings ·
Evofem moved the maturity of convertible notes held by Adjuvant to December 1, 2026, and removed some affirmative covenants. The 8-K gives no repayment plan, and the company's year-end cash was $578,000.
Subject to regulatory approval, the new source is expected to reduce unit costs by 40% or more. Evofem expects to submit a supplemental NDA in mid-2027.
Evofem issued a $706,304 subordinated note to HUB Cyber Security, Ltd. The 12% note matures eleven months after July 8, 2026, and accrues a $2,000 weekly monitoring fee plus a one-time administration fee of $14,126.
Net sales were $0.9 million, up from $0.8 million a year earlier. The CEO said the company looks forward to non-dilutive capital from ex-U.S. partnerships in 2026.
Clovis Davis Pharmaceuticals will lead distribution, promotion, marketing and sales of SOLOSEC in the territory. The release is dated April 27, 2026.
The Fourth Amendment, dated April 10, 2026, makes the notes payable in full at the earliest of three events. It bars prepayment for six months without Adjuvant's consent.
Evofem's sixth amendment to its Aditxt merger agreement adds a new Series G-1 preferred stock to the deal and caps dissenting shares. Common holders share a total of $1,800,000, and the proxy says no fairness opinion was sought.
Evofem Biosciences, Inc. is a San Diego-based commercial-stage biopharmaceutical company focused on women's sexual and reproductive health. Its first commercial product, PHEXX, is described as the first and only non-hormonal prescription contraceptive vaginal gel. The FDA approved PHEXX on May 22, 2020 for the prevention of pregnancy, and it launched in the U.S. in September 2020. In July 2024 the company acquired global rights to SOLOSEC, an FDA-approved single-dose oral antimicrobial agent for bacterial vaginosis and trichomoniasis, and relaunched it in November 2024. Outside the U.S., the company licensed commercial rights to PHEXX and SOLOSEC in the Middle East and North Africa to Pharma 1 Drug Store, LLC in July 2024 and May 2025. Pharma 1 filed for regulatory approval of PHEXX in the United Arab Emirates in June 2025 and of SOLOSEC in September 2025. The company's stated strategy includes lowering manufacturing costs and opportunistically acquiring or in-licensing additional launch-ready products.
| Product or program | What it is | Stage |
|---|---|---|
| PHEXX | Non-hormonal prescription contraceptive vaginal gel | FDA approved May 22, 2020; launched in the U.S. September 2020 |
| SOLOSEC | Single-dose oral antimicrobial for bacterial vaginosis and trichomoniasis | FDA-approved; relaunched November 2024 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $1.8 million | |
| Net income (loss) | $391,000 | -$8.9 million |
| Cash from operations | -$2.0 million | -$3.9 million |
| Cash and equivalents | $578,000 | $741,000 |
Our latest story on this, dated Oct 15, 2026: "Evofem Biosciences pushes Adjuvant note maturity to December 1, 2026". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 26, 2025: "Evofem signs sixth amendment to Aditxt merger agreement". The story links the filing or release it is based on. Read the story.
Evofem Biosciences, Inc. trades under the ticker EVFM on OTC.
Evofem Biosciences, Inc. is listed on OTC.
The SEC Central Index Key (CIK) for Evofem Biosciences, Inc. is 1618835. Its filings are on SEC EDGAR.
132,530,081 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Evofem Biosciences, Inc. under United States.
Our directory classifies Evofem Biosciences, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Evofem Biosciences, Inc. is US30048L3024.
aibio.space lists Evofem Biosciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Evofem Biosciences, Inc. is a San Diego-based commercial-stage biopharmaceutical company focused on women's sexual and reproductive health. Its first commercial product, PHEXX, is described as the first and only non-hormonal prescription contraceptive vaginal gel.
PHEXX: Non-hormonal prescription contraceptive vaginal gel Stage: FDA approved May 22, 2020; launched in the U.S. September 2020.
SOLOSEC: Single-dose oral antimicrobial for bacterial vaginosis and trichomoniasis Stage: FDA-approved; relaunched November 2024.
Evofem Biosciences, Inc. reported net income of $391,000 for the fiscal year ended Dec 31, 2025, and used $2.0 million of cash in operations, per its annual report to the SEC.
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 5.03,5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,5.07,7.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.03,5.03,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported that a debt obligation was accelerated. SEC Form 8-K (Items 1.01,1.02,2.04,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio